<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93890">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01652755</url>
  </required_header>
  <id_info>
    <org_study_id>N-H-Y</org_study_id>
    <nct_id>NCT01652755</nct_id>
  </id_info>
  <brief_title>Plasma Cystatin C and Acute Kidney Injury</brief_title>
  <official_title>Use of Cystatin C in Predicting AKI in Patients Undergone Cardiopulmonary Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinhua Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jinhua Central Hospital</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the utility of plasma cystatin C(pCysC) as a predictive and diagnostic marker of
      acute kidney injury(AKI) in patients undergone cardiopulmonary bypass surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective AKI observational study in patients undergone cardiopulmonary bypass
      surgery. pCysC and plasma creatine will be measured at entry to ICU.AKI was defined as 50%
      increase in plasma creatine above baseline.The predictive and diagnostic performance of
      pCysC will be assessed from area under receiver operator characteristic curve(AUC) and odds
      ratio(OR).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>AKI group</arm_group_label>
    <description>patients with AKI after cardiopulmonary bypass surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-AKI group</arm_group_label>
    <description>patients without AKI during study period</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients undergone cardiopulmonary bypass surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with CPB and admitted to ICU

        Exclusion Criteria:

          -  patients with the age &gt;80 or &lt;18 years

          -  with preexisting renal dysfunction
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongying Ni, MM</last_name>
    <role>Study Chair</role>
    <affiliation>Jinhua municipal central hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongying Ni, MM</last_name>
    <phone>86</phone>
    <phone_ext>57982552629</phone_ext>
    <email>nihongying2@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jinhua central hospital</name>
      <address>
        <city>Jinhua</city>
        <state>Zhejiang</state>
        <zip>321000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongying Ni, MM</last_name>
      <phone>86</phone>
      <phone_ext>57982552629</phone_ext>
      <email>nihongying2@163.com</email>
    </contact>
    <investigator>
      <last_name>Hongying Ni, MM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 3, 2012</lastchanged_date>
  <firstreceived_date>July 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jinhua Central Hospital</investigator_affiliation>
    <investigator_full_name>Hongying Ni</investigator_full_name>
    <investigator_title>Department vice director</investigator_title>
  </responsible_party>
  <keyword>cystatin C,acute kidney injury,</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
